tag emerging-pharma 
PharmaShots
FEBRUARY 17, 2023
Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)
pharmaphorum
MAY 17, 2021
Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) – with a label that will allow it to challenge Alexion’s established therapies directly. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 2, 2020
Few companies embody the term ‘pharma giant’ as much as Pfizer. After the war, Pfizer continued to focus on industrial chemicals as much as medicines, producing the citric acid needed for the emerging soft drinks industry, fuelling brands like Coca Cola and Dr Pepper’s expansion in the 1880s. The era of mega-mergers.
Pharmaceutical Technology
MARCH 22, 2023
The pharmaceutical industry began using radio frequency identification (RFID) tags in the early 2000s. Pfizer was the first to use the tech, adding RFID tags to track a Viagra (sildenafil) shipment circa 2006. Twenty years ago, the cost of implementing RFID tags and the ecosystem (software) was much more expensive than today.
Viseven
SEPTEMBER 14, 2023
The pharma sector now reconsiders its procurement process for improved efficiency, resilience, and cost optimization. Discover the innovative approaches that pharma brands employ to effectively address challenges and drive progress. Climate change is another factor, potentially disrupting supplies and contributing to hefty price tags.
pharmaphorum
NOVEMBER 19, 2021
Indeed, the price tags for Pfizer’s and Moderna’s jabs are substantial. billion, with more than $500 million coming from Europe and $455 million from emerging markets. The market potential for any vaccine currently in trials is lower because the only markets really are the developing countries, which can’t pay the same prices.”.
European Pharmaceutical Review
MAY 11, 2023
What are the emerging modalities in the gene therapy sector? 1 This is assuming a $1M price tag for all gene therapies. In 2015, she joined Astellas Pharma, Northbrook, IL, and served as Global Lead for Immunology, CNS and Neuromuscular Indications and eventually as Global Medical Lead for the Muscle TA.
Expert insights. Personalized for you.
40 
Let's personalize your content